Rong-Hua Song1, Zhi-Yun Yu2, Qiu Qin3, Xuan Wang3, Fatuma-Said Muhali3, Liang-Feng Shi4, Wen-Juan Jiang4, Ling Xiao4, Dan-Feng Li4, Jin-An Zhang4. 1. Clinical Research Center, The First Affiliated Hospital of Medical School of Xi'an Jiaotong University 277 West Yanta Road, Xi'an 710061, China. 2. Xi'an Health School Xi'an 710054, China. 3. Clinical Research Center, The First Affiliated Hospital of Medical School of Xi'an Jiaotong University 277 West Yanta Road, Xi'an 710061, China ; Department of Endocrinology, Jinshan Hospital of Fudan University 1508 Longhang Road, Jinshan District, Shanghai 201508, China. 4. Department of Endocrinology, Jinshan Hospital of Fudan University 1508 Longhang Road, Jinshan District, Shanghai 201508, China.
Abstract
PURPOSE: The aim of this study was to make a comparative analysis of the possible different expression of Th22 cells in two subtypes of autoimmune thyroid diseases (AITDs), i.e., Graves' disease (GD) and Hashimoto's thyroiditis (HT). METHODS: We recruited 61 AITDs patients (31 GD and 30 HT) and 22 controls. Serum level of IL-22 was measured by enzyme linked immunosorbent assay (ELISA). The proportion of Th22 cells in peripheral blood mononuclear cells (PBMCs) was analyzed by flow cytometry. The messenger RNA (mRNA) expressions of IL-22, its receptors (IL10R2, IL22R1) and key transcription factor (aryl hydrocarbon receptor, AHR) in PBMCs were assayed by quantitative reverse transcription polymerase chain reaction (qRT-PCR). Several cytokines of the cultured PBMCs were also measured under IL-22 stimulation. RESULTS: The proportion of Th22 cells, serum IL22 level and IL-22 mRNA expression were significantly higher in patients with GD than in healthy controls. Additionally, AHR increased in GD patients compared to healthy controls. However, the elevation of Th22 cells and their relative cytokines was not found in patients with HT. Consistent with specific mRNAs expression of cultured PBMCs, IL-4 increment in supernatant was much higher in GD group than in control group, while IFN-γ levels were decreased under IL-22 stimulation. CONCLUSION: Th22 cells may participate in the pathogenesis of AITDs as a proinflammatory factor, especially in GD, through expressing and secreting IL-22.
PURPOSE: The aim of this study was to make a comparative analysis of the possible different expression of Th22 cells in two subtypes of autoimmune thyroid diseases (AITDs), i.e., Graves' disease (GD) and Hashimoto's thyroiditis (HT). METHODS: We recruited 61 AITDs patients (31 GD and 30 HT) and 22 controls. Serum level of IL-22 was measured by enzyme linked immunosorbent assay (ELISA). The proportion of Th22 cells in peripheral blood mononuclear cells (PBMCs) was analyzed by flow cytometry. The messenger RNA (mRNA) expressions of IL-22, its receptors (IL10R2, IL22R1) and key transcription factor (aryl hydrocarbon receptor, AHR) in PBMCs were assayed by quantitative reverse transcription polymerase chain reaction (qRT-PCR). Several cytokines of the cultured PBMCs were also measured under IL-22 stimulation. RESULTS: The proportion of Th22 cells, serum IL22 level and IL-22 mRNA expression were significantly higher in patients with GD than in healthy controls. Additionally, AHR increased in GDpatients compared to healthy controls. However, the elevation of Th22 cells and their relative cytokines was not found in patients with HT. Consistent with specific mRNAs expression of cultured PBMCs, IL-4 increment in supernatant was much higher in GD group than in control group, while IFN-γ levels were decreased under IL-22 stimulation. CONCLUSION: Th22 cells may participate in the pathogenesis of AITDs as a proinflammatory factor, especially in GD, through expressing and secreting IL-22.
Authors: Silke Schmechel; Astrid Konrad; Julia Diegelmann; Jürgen Glas; Martin Wetzke; Ekaterini Paschos; Peter Lohse; Burkhard Göke; Stephan Brand Journal: Inflamm Bowel Dis Date: 2008-02 Impact factor: 5.325
Authors: Kristine E Nograles; Lisa C Zaba; Avner Shemer; Judilyn Fuentes-Duculan; Irma Cardinale; Toyoko Kikuchi; Michal Ramon; Reuven Bergman; James G Krueger; Emma Guttman-Yassky Journal: J Allergy Clin Immunol Date: 2009-05-12 Impact factor: 10.793